Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia | Zendy

Andreas Greinacher | Zendy; H. Völpel | Zendy; Uwe Janssens | Zendy; V. Hach-Wunderle | Zendy; B. KemkesMatthes | Zendy; Petra Eichler | Zendy; H. G. Mueller-Velten | Zendy; B. Pötzsch | Zendy

Open Access

Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced Thrombocytopenia

Author(s) -

Andreas Greinacher,

H. Völpel,

Uwe Janssens,

V. Hach-Wunderle,

B. KemkesMatthes,

Petra Eichler,

H. G. Mueller-Velten,

B. Pötzsch

Publication year - 1999

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.99.1.73

Subject(s) - lepirudin , medicine , hirudin , heparin induced thrombocytopenia , heparin , recombinant dna , discovery and development of direct thrombin inhibitors , anticoagulant , platelet , intensive care medicine , pharmacology , surgery , thrombin , biochemistry , chemistry , gene

The immunological type of heparin-induced thrombocytopenia (HIT) is the most frequent drug-induced thrombocytopenia. This study evaluated the efficacy of recombinant hirudin (r-hirudin or lepirudin), a potent thrombin inhibitor, for anticoagulation in patients with confirmed HIT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research